IN2014MN01900A - - Google Patents

Download PDF

Info

Publication number
IN2014MN01900A
IN2014MN01900A IN1900MUN2014A IN2014MN01900A IN 2014MN01900 A IN2014MN01900 A IN 2014MN01900A IN 1900MUN2014 A IN1900MUN2014 A IN 1900MUN2014A IN 2014MN01900 A IN2014MN01900 A IN 2014MN01900A
Authority
IN
India
Prior art keywords
receptor
insulin
methods
growth factor
antibodies
Prior art date
Application number
Inventor
Lutz Schomburg
Waldemar Minich
Siegmund Karasch
Original Assignee
Lutz Schomburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lutz Schomburg filed Critical Lutz Schomburg
Publication of IN2014MN01900A publication Critical patent/IN2014MN01900A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to methods and kits useful in the identification of modulators of the binding properties of antibodies reactive with one or more members of the insulin receptor family selected from the insulin receptor (IR) the insulin like growth factor 1 receptor (IGF1R) the insulin like growth factor 2 receptor (IGF2R) the insulin IGF1 hybrid receptor (IIHR) and the insulin receptor related receptor (IRRR) and methods for the detection of such antibodies.
IN1900MUN2014 2012-02-24 2013-02-25 IN2014MN01900A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12156930.5A EP2631653A1 (en) 2012-02-24 2012-02-24 Identification of modulators of binding properties of antibodies reactive with a member of the insulin receptor family
PCT/EP2013/053707 WO2013124482A2 (en) 2012-02-24 2013-02-25 Identification of modulators of binding properties of antibodies reactive with a member of the insulin receptor family

Publications (1)

Publication Number Publication Date
IN2014MN01900A true IN2014MN01900A (en) 2015-07-10

Family

ID=47915155

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1900MUN2014 IN2014MN01900A (en) 2012-02-24 2013-02-25

Country Status (7)

Country Link
US (2) US20150301040A1 (en)
EP (3) EP2631653A1 (en)
CN (1) CN104126122B (en)
DK (1) DK2817623T3 (en)
ES (1) ES2734124T3 (en)
IN (1) IN2014MN01900A (en)
WO (1) WO2013124482A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102014226663A1 (en) * 2014-12-19 2016-06-23 Charité Universitätsmedizin Berlin Bridge assays for the detection of antibodies against members of the cardiac receptor family
CN109682963B (en) * 2019-01-15 2021-09-21 重庆派金生物科技有限公司 Method for analyzing binding rate of recombinant human insulin and analogues or conjugates thereof and insulin receptor
WO2021074288A1 (en) * 2019-10-16 2021-04-22 Medizinische Hochschule Hannover Non-coding rna protecting against heart failure
CN114675040B (en) * 2022-02-10 2023-02-21 江苏省人民医院（南京医科大学第一附属医院） A kit for detecting intracellular segment antibody of insulin receptor
CN119286866B (en) * 2024-12-13 2025-06-06 青岛农业大学 Application of dsRNA in inhibiting reproductive capacity of bemisia tabaci

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE132267T1 (en) * 1987-10-30 1996-01-15 Abbott Lab IMMUNE TEST USING ANTIGENS PRODUCED IN HETEROLOGUE ORGANISMS
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
PA8535501A1 (en) 2001-01-05 2003-07-28 Pfizer ANTIBODIES AGAINST THE RECEIVER OF THE SIMILAR TO INSULIN GROWTH FACTOR
EP1358211A2 (en) * 2001-01-31 2003-11-05 Mount Sinai Hospital Methods for regulating the kinase domain of ephb2
GB0128583D0 (en) * 2001-11-28 2002-01-23 Rsr Ltd Detection of autoantibodies indicative of diabetes
US7553485B2 (en) 2002-01-18 2009-06-30 Pierre Fabre Medicament Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
WO2003083057A2 (en) * 2002-03-22 2003-10-09 Joslin Diabetes Center, Inc. Adipocytes and uses thereof
US20040209930A1 (en) 2002-10-02 2004-10-21 Carboni Joan M. Synergistic methods and compositions for treating cancer
MXPA05009837A (en) 2003-03-14 2005-12-05 Pharmacia Corp Antibodies to igf-i receptor for the treatment of cancers.
CA2524305C (en) 2003-05-01 2015-12-08 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
DK1656391T3 (en) 2003-08-13 2011-01-03 Pfizer Prod Inc Modified human IGF-1R antibodies
PE20050928A1 (en) 2003-11-21 2005-11-08 Schering Corp THERAPEUTIC COMBINATIONS OF ANTI-IGFR1 ANTIBODY
WO2005058967A2 (en) 2003-12-16 2005-06-30 Pierre Fabre Medicament Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof
RU2342159C2 (en) 2004-07-16 2008-12-27 Пфайзер Продактс Инк. Combined therapy for non-hematologic malignant tumours using anti-igf-1r antibody
FR2873699B1 (en) 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa NOVEL ANTI-IGF ANTIBODIES IR RT USES THEREOF
JP2008533100A (en) * 2005-03-18 2008-08-21 ノボ ノルディスク アクティーゼルスカブ PEGylated single chain insulin
KR20060102592A (en) * 2005-03-24 2006-09-28 바이오제멕스 주식회사 Cancer diagnostic immunocomplex and kit using autoantibody detection method and method using same
CN1773282A (en) * 2005-10-27 2006-05-17 上海交通大学 Autoantibody detection method for the diagnosis of immune-mediated type 1 diabetes
WO2007094395A1 (en) 2006-02-15 2007-08-23 Mie University Method of constructing recombinant proteoliposome for diagnostic use
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
GB0702888D0 (en) * 2007-02-14 2007-03-28 Glaxo Group Ltd Novel Antibodies
CN101256189A (en) * 2007-02-28 2008-09-03 天津市协和医药科技有限公司 Human-outer autoantibody radio-immunity quantitative determination method
CN101825637B (en) * 2009-03-03 2013-01-23 中国人民解放军军事医学科学院基础医学研究所 Composition for immunologically diagnosing type I diabetes
CN101968483A (en) * 2009-07-27 2011-02-09 深圳市菲鹏生物股份有限公司 One-step semi-double-antigen sandwich immunological detection method
EP2564188A4 (en) * 2010-04-26 2013-09-25 Merrimack Pharmaceuticals Inc ASSAYS FOR ANTIBODIES AGAINST BIODIENTS USING ABUNDANT ENDOGENIC PROTEIN ANTAGONISTS OF THIS ACTIVE SUBSTANCE

Also Published As

Publication number Publication date
WO2013124482A3 (en) 2013-12-27
ES2734124T3 (en) 2019-12-04
EP3527988A3 (en) 2019-11-20
US20150301040A1 (en) 2015-10-22
EP2631653A1 (en) 2013-08-28
WO2013124482A2 (en) 2013-08-29
WO2013124482A9 (en) 2014-04-10
EP3527988A2 (en) 2019-08-21
CN104126122A (en) 2014-10-29
DK2817623T3 (en) 2019-07-15
CN104126122B (en) 2017-03-22
EP2817623B1 (en) 2019-05-08
EP2817623A2 (en) 2014-12-31
US20170276675A1 (en) 2017-09-28

Similar Documents

Publication Publication Date Title
AU2018253639A1 (en) Compositions and methods for antibodies targeting EPO
PH12013500933A1 (en) Methods and compositions for neural disease immunotherapy
IN2014CN03042A (en)
AU2012222463A8 (en) Cea antibodies
EP2566890A4 (en) Anti-pai-1 antibodies and methods of use thereof
MX2013004761A (en) Novel egfr-binding molecules and immunoconjugates thereof.
AU2013361107A8 (en) Human anti-tau antibodies
WO2015108998A8 (en) Cartilage targeting agents and their use
WO2013188693A8 (en) Antigen binding constructs to cd3
MX360403B (en) Amyloid-beta binding proteins.
NZ729044A (en) 4-1bb binding molecules
EP4674866A3 (en) Compositions and methods for growth factor modulation
PH12014501410A1 (en) Compositions and methods for antibodies targeting factor p
MX2015003150A (en) Human islet amyloid polypeptide (hiapp) specific antibodies and uses thereof.
AU2012323781A8 (en) Antibodies to CD1d
IN2015DN00139A (en)
PH12015500752A1 (en) Her3 antigen binding proteins binding to the beta-hairpin of her3
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
MX2012011829A (en) Anti-polyubiquitin antibodies and methods of use.
PH12015500751A1 (en) Anti-her3/her4 antigen binding proteins binding to the beta-hairpin of her3 and beta-hairpin of her4
EA201491120A1 (en) ANTIBODIES TO THE RECEPTOR EPIDERMAL GROWTH FACTOR 3 (HER3), DIRECTED TO DOMAIN III AND DOMAIN IV HER3
WO2013124482A9 (en) Identification of modulators of binding properties of antibodies reactive with a member of the insulin receptor family
MX2015004892A (en) Methods and compositions relating to anti-il-21 receptor antibodies.